title: Hemodynamic effects of SIN-1 in acute left heart failure.
abstract: To assess the hemodynamic effects of SIN-1, the active metabolite of the venodilator molsidomine, after acute as well as chronic intravenous administration, ten patients with exacerbation of chronic heart failure were studied. After a mean bolus dose of 2 mg of SIN-1, mean right atrial pressure (MRAP), mean pulmonary artery pressure (MPAP), and pulmonary capillary wedge pressure (PCAP) decreased significantly up to the 60th minute; pulmonary vascular resistance (PVR) decreased significantly up to the 30th minute, while cardiac index (CI) and systemic vascular resistance (SVR) remained unchanged. During a 24-hour continuous infusion of SIN-1, MRAP, MPAP, and PCAP decreased significantly, while CI, PVR, and SVR remained largely unaltered. No dose adjustment was required to maintain the hemodynamic effects over 24 hours. The absence of noteworthy side effects and tolerance during this prolonged administration indicate that SIN-1 is a potentially useful drug in the management of patients admitted with exacerbation of heart failure.
authors.affiliation: Department of Cardiology, Hospital Erasme, Bruxelles, Belgium.
authors.forename: T M
authors.initials: TM
authors.lastname: Ibrahim
authors.forename: P H
authors.initials: PH
authors.lastname: Unger
authors.forename: J
authors.initials: J
authors.lastname: Sobolski
authors.forename: P
authors.initials: P
authors.lastname: Depelchin
authors.forename: M
authors.initials: M
authors.lastname: Jottrand
authors.forename: S
authors.initials: S
authors.lastname: Degre
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D008981:Molsidomine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D014665:Vasodilator Agents; C002385:linsidomine; D008981:Molsidomine